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oRIGINAL ARTICLE
Introduction: Computed tomography-guided transthoracic fine-nee-
dle aspiration (FNA) is a highly sensitive technique for diagnosing 
malignancy in pulmonary nodules; however, there is great uncertainty 
regarding the reliability of a benign result. The goal of this study was 
to characterize the clinical, radiologic, and technical variables associ-
ated with a false negative result.
Methods: We performed a consecutive series review of patients who 
had an initial benign result from an FNA between January 2002 and 
December 2004. Medical charts were reviewed to identify patients 
with false negative and true negative results and determine which 
variables were associated with a missed diagnosis.
Results: one hundred and seventy patients underwent an FNA biopsy 
yielding an initial benign result and had adequate clinical follow-
up. Eighteen of these proved to be false negatives and 152 were true 
negative. Compared with the patients with true negatives, those with 
false negative results had significantly larger nodules (mean, 27 mm 
versus 17 mm, p = 0.04), fewer imaging adjustments per needle pass 
(4.5 versus 6.4, p = 0.01), a higher proportion in whom the needle 
tip was not documented within the lesion (24% versus 5%, p =0.04), 
and a higher pneumothorax rate at any point during the procedure 
(50% versus 22%, p =0.04). When these variables were considered 
jointly, pneumothorax (p = 0.006), solitary nodule (p = 0.04), and the 
radiologist who performed the procedure (p = 0.04) were significant 
predictors of false negative results.
Conclusions: Factors that were associated with false negative results 
include increased size of lesion, fewer adjustments of the needle, lack 
of positive cultures, and the occurrence of a pneumothorax. A benign 
FNA biopsy result should have the procedure reviewed to ensure the 
results are reliable.
Key Words: Lung cancer, Needle biopsy, Early detection, Lung nod-
ule, Fine-needle aspiration.
(J Thorac Oncol. 2012;7: 815–820)
Screening for lung cancer with low-dose computed tomog-raphy (CT) scans has been shown to reduce mortality; 
however, more than 95% of the nodules detected by CT scan 
are ultimately found to be benign.1 Therefore, it is critical to 
develop diagnostic algorithms using the least invasive tech-
niques possible.2–5
When tissue sampling is recommended, CT-guided transt-
horacic fine-needle aspiration (FNA) is a suitable technique 
for pulmonary nodules 5 mm or greater in size.6–8 Given its 
relative safety, this technique is often preferable to surgical 
resection because 18 to 50% of the nodules diagnosed at tho-
racotomy are benign, and significant morbidity and mortal-
ity may accompany thoracotomy or thoracoscopy.9–11 When a 
malignant diagnosis is rendered by FNA, the clinical decision-
making is usually straightforward because of the extremely 
low false-positive rates (0.0–0.2%).12 However, when a benign 
diagnosis is obtained, there is clinical uncertainty over how to 
proceed because an unknown number of these nodules may 
prove to be malignant (false negatives). Previous studies have 
evaluated the outcomes after a benign biopsy and have found 
false negative rates that vary widely (6–54%).12–15
The goals of this study were to characterize the clinical, radio-
logic, and technical (procedure-related) variables associated 
with a missed diagnosis. Previous work has reported that cer-
tain technical variables can affect the accuracy of a needle 
biopsy, such as the presence of a cytopathologist during the 
procedure, the size and type of needle (FNA versus core), and 
the number of passes.15,16 our study sought to identify addi-
tional technical variables and clinical, radiologic, and patho-
logic findings that might assure the patient and physician that 
a benign biopsy result is truly indicative of a benign process. 
In addition, we analyzed the outcomes of patients with false 
negative results to determine if whether there was any clinical 
impact from a delay in diagnosis.
METHODS
Subjects
With approval from the Institutional Review Board at Weill 
Cornell Medical center (Protocol # 0903010284), we reviewed 
the electronic medical records for all patients who underwent 
an FNA lung biopsy performed at New York Presbyterian 
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Hospital, Weill Cornell Medical Center during a 3-year period 
(January 2002–December 2004).
To be included in the study, patients had to have an initial 
“benign” cytology result (meaning that no malignant cells 
were seen on cytologic review) and adequate clinical follow-
up. For adequate clinical follow-up, the biopsied lesion must 
have been followed for at least 2 years by CT demonstrating 
resolution or no growth, or had a definitive surgical biopsy to 
determine the true nature of the lesion. Patients with initial 
cytology results that were classified as malignant (including 
atypical bronchoalveolar proliferation17 or bronchoalveolar 
carcinoma)18,19 or those who underwent an FNA of a non-
parenchymal lesion (e.g., mediastinum or rib) were excluded 
from the analysis.
Initial benign results were further classified into specific 
benign, nonspecific benign, and nondiagnostic. Specific 
benign is defined as a benign lesion (e.g., hamartoma and 
granuloma) or inflammatory cells with a positive bacterial, 
fungal, or mycobacterial culture that could explain the radio-
logic findings. Nonspecific benign is defined as the presence 
of benign cellular material, e.g., inflammatory cells, but not 
specific enough to render a diagnosis. Nondiagnostic biopsy 
result is defined as the presence of normal respiratory elements 
(e.g., benign bronchial cells and macrophages) or blood.
True negative cases were defined as those demonstrating CT 
stability for at least 2 years, resolution of the lesion of interest 
on follow-up imaging, or undergoing a surgical biopsy dem-
onstrating a benign process.3,20 False negative biopsy cases 
were defined as those in whom the diagnosis of a malignant 
nodule was established by pathology from a subsequent surgi-
cal biopsy or repeat FNA.
For patients who were found to have a false negative biopsy, 
further clinical information was collected to determine the 
impact of the delay in diagnosis, the stage of the cancer at 
diagnosis, and the overall outcome of the patient.
Needle-Biopsy Technique
For all biopsies, 1% lidocaine was administered into the sub-
cutaneous tissues and pleural surfaces for local anesthesia. 
A General Electric Lightspeed CT scanner (GE Healthcare, 
Waukesha, WI) was used, with CT parameters set at 120kVp 
for tube voltage, 20 to 40 mAs for tube current, and 1.25 to 
2.5 mm for slice thickness, depending on patient body habi-
tus and nodule size. Under CT guidance, a 22-gauge Westcott 
needle (BD Medical, Franklin Lakes, NJ) was advanced into 
the pulmonary lesion. Samples were obtained and provided to 
an onsite cytologist and when a sufficient amount of specimen 
was available, to the Microbiology Laboratory when there 
was microscopic evidence of inflammation and no evidence 
of cancer. Additional biopsy samples were acquired using a 
new 22-gauge needle if the immediate cytologic evaluation 
revealed an insufficient sample. A postbiopsy CT image was 
obtained to document the development of a pneumothorax. 
All biopsies were performed by one of two radiologists.
Data Collection
A retrospective chart review was performed to extract relevant 
clinical information using a standardized form for all benign 
biopsies. The clinical variables included prior medical condi-
tions, underlying pulmonary disease, smoking status, number 
of pack years, history of prior malignancy, recent (within 3 
months) positron emission tomography (PET) imaging, and 
reason for the initial CT which detected the lesion of inter-
est. Reasons for the initial CT included pulmonary symp-
toms (e.g., cough and dyspnea), surveillance (patients with 
prior solid organ malignancies sent for yearly CT imaging), 
incidental (nodule noted on imaging performed for another 
reason, e.g., abdominal CT or routine chest radiograph), and 
screening (detect early stage lung cancer in asymptomatic 
high-risk subjects).
The radiologic variables analyzed for each patient included the 
size of the lesion of interest, the presence of other (multiple) 
lung nodules, and whether the nodules was solid, part-solid, or 
nonsolid in appearance.
CT images at the time of biopsy were retrospectively reviewed 
by a radiologist experienced in FNA, who was blinded to the 
outcome of the biopsy and who did not perform any of the biop-
sies. The reviewer collected information on the biopsy-related 
variables that may affect the results including the distance 
between the pleura and the nodule margin along the needle 
path, the number of passes with the needle, whether the nee-
dle tip appeared to be within the lesion (technical adequacy), 
and whether there were complications at any point during or 
immediately after the procedure (e.g., pneumothorax detect-
able by CT). In addition, as each adjustment of the needle was 
followed by an imaging series (typically five contiguous thin-
section images), the total number of imaging series during the 
course of the procedure was recorded as an indirect measure of 
procedural difficulty, which can be because of nodule-related 
factors (e.g., size and location) or patient-related factors (e.g. 
motion and body habitus). Difficult-to-access nodules thus 
require more imaging attempts per needle pass. In addition, 
for each procedure the performing radiologist and cytologist 
were also recorded.
Statistical Analysis
False negatives were compared with true negatives in terms of 
clinical, radiologic, biopsy-related, and pathologic variables. 
For categorical variables, a x2 analysis was performed. For 
continuous variables (age, number of pack years, standardized 
uptake value (SUV) score on PET, and nodule size) a two-
sided Student’s t test was performed. As these variables are 
most likely not independent, a multivariate logistic analysis 
was performed to determine which variables jointly discrimi-
nated between false and true negatives. The statistical analysis 
was performed using SAS version 9.2.
RESULTS
one hundred and seventy patients with an initial benign result 
and adequate clinical follow-up were included in the study. 
During the same time frame, 806 malignant diagnoses were 
rendered on the initial FNA biopsy, including 21 patients 
diagnosed with atypical bronchoalveolar proliferation (cyto-
logically abnormal cells from pure bronchioloalveolar car-
cinoma). Among the 170 patients, 18 were “false negatives” 
as they were ultimately proved to be malignant, and 152 who 
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were “true negatives” (Figure 1). The ultimate diagnoses of 
these false negatives were lung cancer (n = 12), lymphoma 
(n = 3), and non-lung metastastic cancer (n = 3).
To identify the characteristics associated with the finding of a 
false negative, we compared the distribution of clinical, radio-
logic, and biopsy-related variables of the false negatives (n = 
18) with that of the true negatives (n = 152) (Table 1). There 
were no significant differences in clinical variables such as 
age, sex, reason for initial CT scan, prior tobacco use or prior 
malignancy, between the two groups. The frequency of PET 
scans or average SUV score were not significantly different.
The radiologic variables revealed a significant difference in 
the size of the nodules, whereby false negatives were larger 
than the true negatives (mean, 27 mm versus 17 mm, respec-
tively p = 0.04). False negatives were also more likely to be 
solitary (89% versus 69%) and less likely to be solid (78% 
versus 92%), although not statistically significant.
Comparison of the biopsy-related parameters showed that false 
negatives had fewer imaging adjustments per needle pass (4.5 
versus 6.4, p = 0.01), a higher proportion of those in whom 
the needle tip could not be verified to be within the lesion 
(24% versus 7%, p = 0.04), and a higher pneumothorax rate 
(50% versus 22%, p = 0.04). The frequency of pneumothorax 
Figure 1. Flow chart of CT-FNA biopsies from 2002–2004.
TABLE 1. Characteristics Associated with False Negatives and True Negatives
False Negatives (n = 18) True Negatives (n = 152)
n % n % p -value
Age mean(range) 69 (range, 47–86) 65 (range, 21–89) 0.13
Sex M/F 8/10 74/78 0.73
Reason for initial CT
 Screening 2 11 22 14 0.74
 Surveillance 3 17 19 13
 Symptoms 6 33 34 22
 Incidental 1 6 22 14
 Unknown 6 33 55 36
Smokers 11 61 100 66 0.69
Pack years 44.9 (range, 15.0–75.0) 42.7 (range, 1.0–120) 0.81
Prior malignancy 8 44 58 38 0.60
Had PET scan 9 50 87 57 0.56
Average SUV 2.7 (range, 0–8.2) 3.8 (range, 0–14.5) 0.53
Size of nodule (mm) 27.4 (range, 7.5–70.5) 16.7 (range, 4.0–60) 0.04
Solitary nodule 16 89 89 69 0.08
Solid nodule 14 78 140 92 0.07
Distance from pleura to nodule (mm) 21.2 (range, 0.0–77) 20.1 (range, 0.0–83) 0.83
Number of Passes 1.7 (range, 1.0–3.0) 1.7 (range, 1.0–4.0) 0.89
Imaging adjustments per pass 4.5 (range, 2.0–9.3) 6.4 (range, 1.0–16.0) 0.01
# with needle tip in lesion
 No 4 24 9 7 0.04
 Yes 13 76 114 93
Pneumothorax 6 50 27 22 0.04
Positive Culture
 MAI 1 6 13 9 0.90
 Bacteria 0 0 8 5
 Fungus 0 0 3 2
P values in bold and italics are significant.
CT, Computed tomography; PET, Positron emission tomography; MAI, Mycobacterium avium intracellulare.
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increased with increasing imaging attempts per needle pass 
(p = 0.02). Among the negative biopsy results for each radi-
ologist, the proportion of false negatives varied between 8% 
(11/131) and 18% (7/39) (p = 0.13). Because biopsy-associ-
ated factors are interrelated, we performed a logistic regression 
analysis to determine which were significant. Logistic regres-
sion identified three variables which predicted a false negative 
result, pneumothorax (p = 0.006), solitary nodule (p = 0.04), 
and radiologist performing the procedure (p = 0.04). There 
was no significant difference between the reported cytology 
results between the patients with false negative results and 
true negatives, including the distribution of specific, nonspe-
cific, and nondiagnostic results, which pathologist interpreted 
the specimen, and whether there were inflammatory, necrotic, 
or granulomatous features present.
Table 2 lists the reasons for the 18 missed diagnoses. In 
seven cases, the pathologist noted the presence of abnormal 
cells in the cytology specimen, but this was insufficient to 
render a malignant diagnosis. In three, later proven to be 
lymphomas, the cytology was believed to represent inflam-
mation with a preponderance of lymphocytes being noted. 
In four, the needle tip was not documented to be inside 
TABLE 2. Outcomes After a False Negative CT-FNA Biopsy
Delay in 
Diagnosis (mos)
Initial 
Clinical 
Stage by CT
Final Clinical 
Stage at 
Diagnosis
Initial Diagnosis Final Diagnosis Reason for Missed 
Diagnosis
6.0 IB IIB Marked acute inflammation with rare 
sheets and single glandular cells with 
alterations most likely reactive.
Adenocarcinoma Abnormal cells noted
15.0 IA IA Hemosiderin-laden macrophages and a 
cluster of plasmacytoid cells.
Adenocarcinoma Abnormal cells noted
16.0 IA IA Acellular material, blood, and rare 
histiocytes and reactive mesothelial cells.
Adenocarcinoma Acellular sample
11.0 IA IA organizing pneumonia with mild 
bronchioloalveolar proliferation.
Adenocarcinoma Abnormal cells noted
2.0 IIIB IIB Benign bronchial epithelium and 
pulmonary macrophages.
Adenocarcinoma Needle not in lesion
4.0 IA IA Ciliated bronchial cells and histiocytes. Adenocarcinoma Needle not in lesion
3.0 IV IV Acute granulomatous inflammation 
with marked, focal reactive atypia of 
bronchioloalveolar cells.
Adenocarcinoma Abnormal cells noted
1.0 IB IA Acute inflammation. Carcinoid Biopsy in 
postobstructed lung
8.0 N/A N/A Clusters of reactive bronchial cells, some 
foamy macrophages.
Lymphoma Mistaken for 
inflammation
8.0 N/A N/A Chronic inflammatory cells, favor an 
organizing pneumonia.
Lymphoma Mistaken for 
inflammation
4.0 N/A N/A organizing pneumonia. Lymphoma Mistaken for 
inflammation
5.0 Metastatic Metastatic Reactive bronchial epithelium, and 
hemosiderin-laden pulmonary 
macrophages.
Melanoma Needle not in lesion
0.5 IV IV Marked necrosis, clusters of reactive, cells 
and atypical squamous metaplasia; an 
inflammatory pseudotumor is suspected.
Mesothelioma Needle not in lesion
70.0 Metastatic Metastatic Nonspecific lung aspirate composed of 
blood, rare foreign-body giant cells, and 
alveoli without pneumocyte hyperplasia.
Metastatic renal 
cell
Acellular sample
0.2 IA IA Inflammation and necrosis, one cluster of 
glandular cells with secretory cytoplasm.
Mucinous colloid 
carcinoma
Abnormal cells noted
1.0 IV IV Acute pneumonia, markedly atypical type-
II pneumocytes in a background of acute 
pneumonia.
NSCLC Abnormal cells noted
32.0 IA IA Numerous fungal hyphal forms, with an 
acute inflammatory cell infiltrate.
NSCLC Misread as artifact
12.0 IIIB IIIB Macrophages, groups of ciliated, reactive 
bronchial cells, and a cluster of 
dysplastic squamous cells.
Squamous cell Abnormal cells noted
Median delay 4.5
NSCLC, Non–small cell lung cancer.
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the lesion, acellular aspirate was seen in two cases, and 
another appeared to be a misread as an artifact during sam-
ple processing. In one case, the needle appeared to be in the 
postobstructive lung (Figure 2). This patient had the only 
positive biopsy culture among the false negatives, and that 
case grew Mycobacterium Avium Intracellulare, compared 
to 24 positive cultures among the true negatives (16%).
of the 18 false negatives, six had a repeat CT FNA which 
resulted in a diagnosis of malignancy: in one, the initial onsite 
cytological interpretation suggested fungal disease which 
prevented further passes; in another, the needle tip was not 
documented as being in the lesion. In the remaining four, the 
needle tip was documented to be in the lesion at the time of 
the biopsy and two passes were made. Subsequent needle 
biopsy in these four cases resulted in the diagnosis of meta-
static renal carcinoma (bloody aspirate), lymphoma, adeno-
carcinoma in a nonsolid nodule, and adenocarcinoma in a 
solid nodule. In addition, for one patient, the cytology was re-
reviewed 3 months later, which resulted in a correct diagnosis 
of adenocarcinoma.
Table 2 shows the initial and final clinical stages and the 
time between the FNA biopsy and surgery/repeat FNA. 
Median delay in diagnosis was 4.5 months, ranging from 
0.2 to 70 months. only one of the 18 patients had a higher 
clinical stage at diagnosis than the clinical stage of the ini-
tial biopsy (#1). This patient was clinical stage IB based 
on CT findings at the time of the FNA and at preoperative 
imaging and surgery 6 months later was found to have a 
malignant hilar lymph node, thus clinical and pathologic 
stage IIB at diagnosis.
DISCUSSION
our first objective was to identify clinical, technical, patho-
logic, or radiologic characteristics that were associated with 
false negative results. our time frame between 2002 and 2004 
was selected to allow for adequate clinical follow-up after the 
biopsy.
The first variable that was significantly associated with false 
negative results was the size of the nodule. one might expect 
that larger lesions would be more accessible and therefore 
easier to biopsy and that smaller nodules would be more 
prone to missed diagnoses. However, our study demonstrated 
that false negatives tended to occur in larger lesions, a result 
noted previously.21 We speculate that the portion of the lesion 
with malignant cells was likely part of a larger consolidation, 
making it difficult to distinguish the primary lesion from sur-
rounding atelectasis or inflammation. It may also be related 
to an increased amount of inflammation or necrosis in larger 
nodules.
Another variable that was significantly different in the false 
negative group was the number of imaging adjustments that 
were made for each needle pass during the biopsy. The true 
negative biopsies had on an average 6.4 imaging adjustments 
compared to 4.2 for the false negatives. one explanation for 
this could be more attentive and careful placement of the nee-
dle during the true negative biopsies, although documentation 
of the tip of the needle in the lesions should ultimately be the 
most important criteria. Another reason for the fewer imaging 
adjustments is that the larger lesion size of the false negative 
cases provided an easier target.
our study revealed a significant association between the radi-
ologist performing the procedure and the rate of false nega-
tives, suggesting it is operator dependent. Although both 
radiologists were experienced with CT FNA, the operator 
with the lower incidence of false negatives had more years of 
experience with the procedure and performed more biopsies 
in general.
one limitation of our study is that all the biopsies were 
performed using BD Westcott single-shaft (non-coaxial) 
22-gauge needles. The use of this single-shaft needle is based 
on the individual radiologist’s preference and experience. In 
a recent survey conducted among 139 thoracic and interven-
tional radiologists, about half of the radiologists preferred this 
single-shaft needle over a coaxial needle.22 The commonly 
cited benefits of the single-shaft needle include a smaller cali-
ber and increased needle flexibility. A commonly cited disad-
vantage of the single-shaft needle is the need for a new pleural 
puncture for each needle pass.
Previous reports have suggested that additional number of sam-
ples will improve the yield of this procedure. our results showed 
that pneumothorax was the main limiting factor, as it limited the 
ability to put the needle tip in the lesion and also limited the 
number of passes. However, as six cases with an initial negative 
result underwent repeat FNA which yielded the diagnosis of 
malignancy, it does suggest that additional sampling at the time 
of the initial procedure might have yielded the correct result. 
The reason that additional samples were not obtained at the 
time of the procedure is not known as this was not specifically 
recorded. It could either be that the operator felt the amount of 
Figure 2. CT image of CT FNA performed in a patient with 
a postobstructive pneumonia. Thin arrow is pointing to the 
tip of the fine needle inside the consolidated lung and the 
thick arrow is pointing to the central obstructing tumor: in 
this case, a carcinoid tumor.
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tissue was sufficient or that the patient was unable or unwilling 
to continue to have additional samples obtained.
In the false negative group, there was one patient out of 18 (6%) 
with a positive culture, compared with the true negative group 
of which 24 of 152 patients (16%) had positive cultures. The 
positive culture in the false negative group occurred in a case 
where the postobstructed lung was suspected. Therefore, the 
predictive value that a positive culture from a benign biopsy is 
a true negative result is 97% (34 positive cultures that are true 
negative out of 35 positive cultures in total). Given the low 
likelihood of a false positive culture, one can conclude that 
the presence of a positive culture on an FNA (when there is no 
suspicion of postobstructive pneumonia) strongly supports the 
likelihood that this is truly a benign lesion.
one criticism of the FNA is that the procedure may be super-
fluous and delay resection. For the 18 false negatives cases, the 
median delay in diagnosis, from initial benign needle biopsy to 
definitive diagnosis of malignancy, was 4.5 months. A single 
case had a clinical stage IB and was found to be clinical stage 
IIB 6 months later. Previous studies have also demonstrated 
no harm to the patient when there is a delay in diagnosis pro-
vided that there is continued surveillance of an indetermi-
nate lesion.23,24 The relatively large number of patients with 
true negative results suggests that a significant proportion of 
patients may have been spared unnecessary surgery. Therefore, 
the benefits of FNA, whereby patients avoid unnecessary sur-
gery, may outweigh the harms (delay in diagnosis for a small 
percentage of patients, complication from the procedure).
In conclusion, this study demonstrates that factors associated 
with false negative results from an FNA include increased 
size of lesion (which may have led to sampling error), fewer 
adjustments of the needle, the lack of positive cultures, and the 
occurrence of a pneumothorax. When a benign cytology result 
is obtained, the procedure should be reviewed to look for the 
presence of any of the above factors. False negative FNA in 
the diagnosis of pulmonary nodules is relatively uncommon 
and with careful monitoring rarely affects outcomes. We rec-
ommend that benign FNA biopsies have repeat imaging for at 
least 2 years to document stability or resolution of the lesion. 
If the nodule grows, then repeat biopsy or resection may be 
required to obtain a definitive diagnosis.
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